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ABSTRACT
CD99 is a cell surface molecule that has emerged as a novel target for Ewing
sarcoma (EWS), an aggressive pediatric bone cancer. This report provides the first
evidence of methuosis in EWS, a non-apoptotic form of cell death induced by an
antibody directed against the CD99 molecule. Upon mAb triggering, CD99 induces
an IGF-1R/RAS/Rac1 complex, which is internalized into RAB5-positive endocytic
vacuoles. This complex is then dissociated, with the IGF-1R recycling to the cell
membrane while CD99 and RAS/Rac1 are sorted into immature LAMP-1-positive
vacuoles, whose excessive accumulation provokes methuosis. This process, which is
not detected in CD99-expressing normal mesenchymal cells, is inhibited by disruption
of the IGF-1R signaling, whereas enhanced by IGF-1 stimulation. Induction of IGF1R/RAS/Rac1 was also observed in the EWS xenografts that respond to anti-CD99
mAb, further supporting the role of the IGF/RAS/Rac1 axis in the hyperstimulation of
macropinocytosis and selective death of EWS cells. Thus, we describe a vulnerability
of EWS cells, including those resistant to standard chemotherapy, to a treatment with
anti-CD99 mAb, which requires IGF-1R/RAS signaling but bypasses the need for their
direct targeting. Overall, we propose CD99 targeting as new opportunity to treat EWS
patients resistant to canonical apoptosis-inducing agents.

patients have very poor prognosis and treatment remains
a challenge. The characterization of EWS genomes has
poorly contributed to the identification of novel therapeutic
strategies. EWS shows very low rate of somatic mutations
[1, 2] confirming the dependence of this tumor on the
oncogenic chimeric EWS–FLI1 protein [3]. However,
as a transcription factor, EWS–FLI1 is a puzzling drug
target [4], and current therapy of EWS still depends on
conventional cytotoxic drugs with no alternative options
for patients relapsing after first line therapies. This is

INTRODUCTION
Ewing sarcoma (EWS) is a malignant mesenchymal
tumor of children and young adults, with unmet clinical
solution and relevant social impact. Despite the use of
intensive multidrug treatments combined with surgery
and/or radiotherapy, this highly invasive bone tumor
forms lung and/or bone metastases in about 30-40% of
patients with localized tumor, while approximately 30% of
patients have detectable metastasis at diagnosis. Metastatic
www.impactjournals.com/oncotarget
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relevant being EWS generally resistant to apoptotic cell
death. Mechanisms of resistance rely on either alterations
of the glutathione pathway [5], or the constitutive
activation of the IGF-1R, TRKB, ErbB4 [6], caveolin-1
or PKCα [7], which may determine patients prognosis.
The identification of novel mechanisms inducing cell
death independently of canonical apoptosis is therefore
imperative for developing new therapeutic approaches for
EWS patients.
A potential method to kill cancer cells in a caspaseindependent mechanism is the hyperstimulation of
macropinocytosis, which can induce a form of nonapoptotic cell death, known as methuosis, death by
macropinocytosis or catastrophic vacuolation [8-11].
This process is characterized by extreme accumulation
of vacuoles in the cytoplasm, which compromises cell
viability [12]. Methuosis was originally described after
ectopic expression of the oncoprotein H-RAS in human
glioblastoma, gastric carcinoma and osteosarcoma cells
[13]. More recently, the demonstration that methuosis
can be induced by different triggers (miRNAs, small
molecules) in other tumors, such as papillary thyroid
carcinoma [14], neuroblastoma [10], prostate cancer,
breast, renal and lung cancer cells [15], has raised
the possibility that agents capable of disrupting the
physiological macropinosome trafficking pathways might
be exploited for inducing cancer cell death.
CD99, a cell surface molecule [16] involved
in several biological processes including migration,
cell death and differentiation [17-19], is consistently
highly expressed in EWS cells and is crucial for EWS
malignancy. In this paper, we demonstrate that CD99
engagement by the 0662 anti-CD99 monoclonal antibody
(mAb) [20, 21] induces cell death of EWS cells through
a non-apoptotic pathway resembling methuosis, which
requires the activation of insulin-like growth factor
receptor 1 (IGF-1R) [22, 23] and RAS-Rac1 downstream
signaling. These data define a novel role for CD99 and
the IGF-1R/RAS pathway in methuosis and identify
a novel targeting approach for EWS cells, including
chemoresistant variants.

patient-derived EWS cell lines, including chemotherapyresistant variants, are all sensitive to CD99-induced cell
death (Supplementary Table S1). Sensitivity of EWS cells
to anti-CD99 antibodies correlated with the status of p53
(p=0.048, Fisher’s exact test).
However, loss of cell viability associated with
CD99 engagement is not prevented by the caspase
inhibitor z-VAD-fmk and dying cells lack features
typical of canonical apoptosis (cell shrinkage, chromatin
condensation, DNA fragmentation) [21]. Electron
microscopy analysis showed that anti-CD99 mAb (3μg/
ml, 30 min) induced massive vacuolization of EWS cells
(Figure 1). The vacuoles observed in LAP-35 (Figure 1A)
and 6647 (not shown) EWS cell lines were of various
size (diameter range: 0.3-2.5μm), and characterized by a
single membrane (Figure 1A: arrows), features consistent
with macropinosomes [11]. Mitochondria and the double
membrane typical of autophagosomes were rarely
observed, suggesting that CD99-associated cell death
might be related to methuosis [12], which is characterized
by progressive accumulation of cytoplasmic vacuoles
originating from macro- and/or micro-pinosomes [25].
Accordingly, necrostatin-1, an allosteric inhibitor of the
death domain receptor-associated adaptor kinase RIP1
which is involved in necroptosis, did not protect LAP35 cells from CD99-induced cell death (Supplementary
Figure S1A). Similarly, treatments with either the
autophagy inhibitor 3-methyladenine (3-MA), that
prevents autophagosome formation, or knock-down
of ATG7, a member of autophagic machinery, did not
reduce CD99-mediated cytotoxicity (Supplementary
Figure S1B and S1C), despite the accumulation of LC3IIB in LAP-35 EWS cells (Supplementary Figure S1D)
and a punctuate pattern of LC3 distribution as detected
by immunofluorescence analysis (Supplementary Figure
S1E). These results indicate that autophagy, even if
induced, is likely a compensatory stress response to
anti-CD99 antibody treatment rather than a cell death
mechanism.
Methuosis relies on the initial formation of vacuoles
through clathrin-independent endocytosis and the
progressive accumulation and enlargement of vacuoles
up to the point of cytoplasmic membrane disruption [12].
Gene expression profile of 6647 EWS cells treated with
anti-CD99 0662mAb suggests disruptions in endocytic
processes (Supplementary Table S2). Enrichment analysis
using Kyoto Encyclopedia of Genes and Genomes
(KEGG) annotations revealed that the majority of
positively modulated genes were related to endocytosis/
lysosomal pathways, particularly after 60 and 120 min
of treatments (Supplementary Table S2). Induction
of endocytic-like processes by anti-CD99 mAb was
confirmed by a rapid (30 min) incorporation of tracer
lucifer yellow (LY), a hallmark of macropinosomes, in
6647 and LAP-35 cells after engagement of CD99 by
0662mAb (Figure 1B and 1C), while internalization of LY

RESULTS
CD99 triggering by 0662mAb induces massive
macropinocytosis that results in cell death
CD99 promotes cancer cell death when triggered
by specific antibodies, such as 0662, O13 murine mAbs
or the human single chain fragment variable diabody
(dAbd C7) [20]. Engagement of CD99 with antibodies
induced fast (within 15 min) and massive annexin V
exposition to the outside layer of cell membrane, MDM2
ubiquitination and degradation, reactivation of p53
signaling and mitochondrial depolarization [20, 21].
All EWS cells express CD99 [24] and we found that 13
www.impactjournals.com/oncotarget
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Figure 1: CD99 engagement by 0662 monoclonal antibody induces macropinocytosis in EWS cells. A. Transmission

electron microscopy of untreated (CTR) or 0662mAb-treated LAP-35 cells (scale bar 2μm). The right panel is a magnification of mAbtreated sample (scale bar 0.5μm). Arrows indicate empty vacuoles, void of cytoplasm and organelles. B. Lucifer yellow (LY) accumulation
in 6647 or LAP-35 EWS cells in presence or not of Cytochalasin D (Cyto D) after 30 min 0662mAb exposure. Images were acquired with a
Nikon ECLIPSE 90i with Plan Apo 60x/NA 1.4 DIC N2 (scale bar 20μm). C. Percentage of LY-positive 6647 and LAP-35 cells in presence
or absence of 0662mAb (30 min) and/or Cyto D (60 min pretreatment). Results are represented as mean ± SEM of three independent
experiments (*p<0.05, Student’s t test).
www.impactjournals.com/oncotarget

79927

Oncotarget

was very modest in untreated cells. The phenotype was
prevented by the macropinocytosis inhibitor cytochalasin
D (Figure 1B and 1C).
As EWS cells are not the best model to study
endocytosis, having large nuclei, small cytoplasm and
growing in suspension, we alternatively used U-2 OS
osteosarcoma cells transfected with CD99 [26]. Treatment
of EWS or osteosarcoma U2/CD99wt57 cells with
0662mAb triggered CD99 internalization, as shown by a
significant decrease of CD99 cell surface levels measured
by both flow cytometry (Figure 2A) and ELISA assay
(Figure 2B).
CD99 significantly colocalized with caveolin-1,
a major component of caveolae, while very limited
colocalization was observed between CD99 and clathrin
in both LAP-35 and U2/CD99wt57 cells (Figure 2C;
Supplementary Figure S2A). Inhibition of clathrindependent pathways with chlorpromazine did not prevent
LY uptake after treatment with anti-CD99 0662mAb
(Figure 2D), indicating that CD99-induced vacuoles
derive from macropinocytosis occurring preferentially
through a caveolin-1-enriched, but clathrin-independent
pathway.
CD99-induced macropinocytic vacuoles contain
the small GTPase RAB5, a marker of early endosomes,
as well as the late endosomal/lysosomal marker LAMP-1
(Supplementary Figure S2B). In fact, CD99 colocalized
with both RAB5 and LAMP-1. Colocalization between
CD99 and RAB5 was observed after 30-60 min, while
colocalization with LAMP-1 was observed after 3h of
antibody treatment and sustained up to 6h (Supplementary
Figure S2B). Thus, CD99 triggering activates an endocytic
pathway, which induces CD99 sorting into lysosomeslike structures. However, as described for methousis
[12], CD99-induced vacuoles are not sufficiently acidic
to sequester lysosomotropic dyes (not shown) or to allow
acridine orange emission to change to orange/yellow
(Supplementary Figure S2C), thus indicating that they are
not fully functional lysosomes. Instead, these structures
progressively accumulate in the cytoplasm, thereby
compromising cell viability.

In fact, engagement of CD99 did not alter transcription
of the IGF-1R (Supplementary Figure S3A). In contrast,
EWS cells stably or transiently overexpressing MDM2
showed reduced levels of IGF-1R in basal condition
and upon CD99 engagement (Supplementary Figure
S3B and S3C), confirming that the modulation of IGF1R levels occurs through stabilization of the protein. In
addition, the IGF-1R and RAS proteins colocalized as
demonstrated by confocal microscopy (Figure 3B) and
coimmunoprecipitated with CD99 in LAP-35 cells (Figure
3C). Similar results were recapitulated in U2/CD99wt57
cells (Figure 3D and 3E).
Activated forms of RAS and the IGF-1R play an
important role in regulating caspase-independent cell
death, associated with cytoplasmic vacuolization [11, 13,
29]. In our cellular models, RAS and the IGF-1R were
both internalized and sorted into early endosomes, as
indicated by colocalization with RAB5 (Figure 4A and
4C), but while RAS followed CD99 and colocalized
with LAMP-1 in late endosomes/lysosome-like vacuoles
(Figure 4B), the IGF-1R did not (Figure 4D; Mander’s
overlap < 0.6) and colocalized instead with RAB11
(Figure 4E), a marker of the recycling compartment [30].
Accordingly, triggering of CD99 by 0662mAb
in presence of cycloheximide, an inhibitor of protein
synthesis, induced partial degradation of CD99 and
RAS but not IGF-1R down-regulation (data not shown).
Thus, in contrast to CD99 and RAS, which are partially
down-regulated upon antibody treatment, the IGF-1R
is likely recycled to the cell surface in RAB11-enriched
compartments.
In TC-71 cells silenced for IGF-1R expression
(Supplementary Figure S4A), treatment with antiCD99 0662mAb failed to induce cell death, (Figure
5A, Supplementary Figure S4B), RAS up-regulation
(Figure 5A, Supplementary Figure S4C) and massive
vacuolization significantly induced in TC-71 parental
cells (Figure 5B, Supplementary Figure S4D). Conversely,
inhibiting IGF-1R action in TC-71 EWS cells by either
anti-IGF-1R neutralizing human antibody (hAb) AVE1642
[31] or the tyrosine-kinase inhibitor NVP-AEW541 [32]
reduced CD99-induced cell death, RAS up-regulation and
inhibited massive vacuolization (Figure 5C), indicating
that CD99-mediated cell death requires a functional
IGF-1R. The effect of the tyrosine kinase inhibitor NVPAEW541 was stronger than that one observed after
AVE1642 treatment, further suggesting that the IGF-1R
activation likely contributes to anti-CD99 mAb activity.
Accordingly, IGF-1 stimulation (50ng/ml, 15 min) of TC71 EWS cells significantly (p-value=0.0226) increased
the percentage of dead cells, promoted RAS up-regulation
and led to massive vacuolization (Supplementary Figure
S4E, S4F and S4G). Overall, these results indicate that
the IGF-1R is necessary for CD99-driven RAS induction
and cell vacuolization. In glioblastoma RAS-induced
cytoplasmic vacuolization does not require the activation

CD99-induced methuosis requires activation of
IGF-1R and RAS-Rac1 signaling
We previously reported a marked and rapid decrease
of MDM2 protein levels following CD99 engagement
[20]. MDM2 is an E3 ubiquitin ligase that antagonizes
the tumor suppressor p53 [27]. In addition, MDM2 serves
as an ubiquitin ligase for the IGF-1R, thereby promoting
receptor degradation [28]. Thus, CD99 engagement, by
altering MDM2 stability, may affect IGF-1R action and
signaling. Accordingly, we detected induction of the IGF1R and its downstream effector RAS following CD99
engagement (Figure 3A). Increased levels of IGF-1R are
likely due to reduced degradation mediated by MDM2.
www.impactjournals.com/oncotarget
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Figure 2: CD99 is internalized after 0662mAb exposure. A. Intensity of CD99 surface expression before (-) and after (+) 0662mAb

treatment (60 min) by flow cytometry. Results are represented as mean ± SEM of three independent experiments (*p<0.05, Student’s t
test). B. CD99 surface expression in 6647 cells by ELISA assay after 0662mAb treatment. Optical density was measured at 405nm. Data
indicate mean relative CD99 expression ± SEM, referred to control absorbance. C. Colocalization between CD99 and Caveolin-1 or CD99
and Clathrin in LAP-35 cells before (CTR) and after 0662mAb treatments is shown by confocal microscopy. CD99 was labeled in green,
Caveolin-1 or Clathrin in red (scale bar 20μm) (*p<0.05, Student’s t test). Colocalization analysis was calculated by Nis Elements AR4.20.01
software (Nikon) and MCC was represented by histograms, as mean ± SEM of an average of one hundred cells from at least 10 independent
fields. D. LY uptake in EWS cells exposed to 0662mAb for 30 min in presence or not of Chlorpromazine (10μg/ml) (scale bar 20μm). Left
panels: representative images of LAP-35 cells. Right panels: percentage of LY-positive 6647 or LAP-35 cells in presence or absence of
0662mAb and/or Chlorpromazine. Results are represented as mean ± SEM of three independent experiments (Student’s t test: n.s).
www.impactjournals.com/oncotarget
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Figure 3: CD99, IGF-1R and RAS interact upon 0662mAb exposure. A. Western blot analysis of IGF-1R and pan-RAS on cell

lysates from control (-) or 0662mAb-treated (+) EWS cells at the indicated times. Equal sample loading was monitored by anti-GAPDH
blotting. B. Confocal microscopy shows colocalization between endogenous CD99 and IGF-1R (left panel) or CD99 and RAS (right
panel) in LAP-35 before (CTR) and after treatment with 0662mAb. Representative images are shown. CD99 was labeled in green, IGF1R or RAS in red (scale bar 20μm). Values are expressed as mean ± SEM (***p<0.001, Student’s t test). C. Coimmunoprecipitation of
endogenous IGF-1R, RAS and CD99 in LAP-35 before and after treatment with 0662mAb. D. Confocal microscopy shows colocalization
between endogenous CD99 and IGF-1R (left panel) or CD99 and RAS (right panel) in U2/CD99wt57 cells before and after treatment with
0662mAb. CD99 was labeled in green, IGF-1R or RAS in red (scale bar 20μm) (***p<0.001, Student’s t test). E. Western blot analysis of
IGF-1R and pan-RAS on cell lysates from control (-) or 0662mAb-treated (+) U2/CD99wt57 cells. Loading was monitored by anti-GAPDH
blotting. Colocalization analysis was calculated by Nis Elements AR4.20.01 software (Nikon) and MCC was represented by histograms as
mean values ± SEM (***p<0.001, Student’s t test).
www.impactjournals.com/oncotarget
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of MAPK or PI3K pathways [33]. Accordingly, the MEK
inhibitor PD98059 or the Akt inhibitor LY294002, as well
as wortmannin, did not block the induction of cell death in
our EWS cellular models [21]. In addition, the suppression
of ERK phosphorylation in 6647 and LAP-35 EWS cells
by stable expression of h-RAS N17 (Supplementary Figure
S5A), a dominant negative form of RAS that inhibits

MAPK/ERK but not Rac1/JNK responses [34], did not
affect but rather increased vacuolization (Supplementary
Figure S5B) and cell death (Supplementary Figure S5C)
upon CD99 triggering.
On the contrary, no induction of vacuolization
(Figure 6A) and a significant reversion of CD99induced cell death was observed in EWS cells when we

Figure 4: RAS and IGF-1R are sorted into early endosomes but the latter is recycled to the cell surface. Confocal
microscopy in U2/CD99wt57 before (CTR) and after 0662mAb treatment shows colocalization for: A. RAS (green) and RAB5 (red);
B. RAS (green) and LAMP-1 (red); C. IGF-1R (green) and RAB5 (red); D. IGF-1R (green) and LAMP-1 (red); E. IGF-1R (red) and
RAB11 (green) (scale bar 20μm). Representative images are displayed. Colocalization analysis was calculated by Nis Elements AR4.20.01
software (Nikon) and MCC was represented by histograms as mean values ± SEM. (***p<0.001, Student’s t test).
www.impactjournals.com/oncotarget
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Figure 5: IGF-1R expression and activity are required for CD99-mediated methuosis. A. CD99-induced cell death in

parental or IGF-1R silenced TC-71 cells (Annexin V/PI) (upper panel). Results are represented as mean ± SEM of three independent
experiments (*p<0.05, Student’s t test). Western blotting evaluation of pan-RAS levels before (-) and after (+) treatment with 0662mAb in
corresponding cells (lower panel). B. Vacuolization was assessed by Acridine Orange staining (AO) after 0662mAb treatment in parental
(TC-71) or IGF-1R silenced cells (TC-siIGF1R#59) (scale bar 20μm). C. Experiments were performed in TC-71 cells before (-) and after
(+) 15 min treatment with 0662mAb alone or in presence of either hAb AVE1642 or NVP-AEW541 (Annexin V/PI). Histograms (upper left
panel) represent mean percentage ± SEM of dead cells (*p<0.05, Student’s t test); western blotting (upper right panel) evaluates pan-RAS
levels in the same conditions. Lower panels display AO staining before (CTR) and after 3h treatment with 0662mAb alone or in presence
of either hAb AVE1642 or NVP-AEW541. For AO staining, cells were acquired using the microscope Nikon ECLIPSE 90i with Plan Fluor
40x/0.75 DIC M/N2. Pictures provided in the figures are all merged images.
www.impactjournals.com/oncotarget
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used either the specific Rac1 inhibitor EHT 1864 [35]
(Figure 6B) or when endogenous Rac1 was depleted by
siRNA approaches (Figure 6C). These results strongly
indicate that the CD99/IGF-1R/RAS-mediated induction
of methuosis in EWS occurs independently of MAPK/
ERKs signaling but through Rac1 protein, a regulator
of actin polymerization and a positive regulator of
macropinocitosis and phagocytosis [36, 37]. Accordingly,
Rac1 colocalized with CD99, RAB5 and LAMP-1 in
vacuoles following the same kinetics previously observed
for RAS (Figure 7A, 7B and 7C). Up-regulation of IGF1R, RAS and Rac1 was also clearly detectable in 6647
xenografts after treatment with anti-CD99 mAb [20, 38]
and Rac1-positive vesicles can be identified in responsive
tumors (Figure 8A and 8B, arrows).

not induce macropinocytosis and massive vacuolization
(Figure 9A) and cells showed minimal increase in RAS
expression after CD99 triggering (Figure 9B).
On the contrary, when the murine C3H10T1/2
mesenchymal cells transfected with both EWS-FLI1 and
CD99 were treated with the 0662mAb, they underwent
catastrophic vacuolization, restored RAS induction (Figure
9C) and died [20]. Conversely, EWS cells resistant to the
anti-CD99 0662mAb because of decreased CD99 levels
on cell surface (6647/CD99low) did not induce RAS upregulation and cytoplasmic vacuolization, when exposed
to the antibody (Figure 9D). These data indicate that
aberrant high expression of CD99 is absolutely required
to activate catastrophic vacuolization and death.
These results additionally support the validity and
specificity of anti-CD99 antibodies as a therapeutic tool
for EWS treatment.

CD99-induced methuosis is selective for cancer
cells highly expressing CD99

DISCUSSION

We have previously demonstrated that engagement
of CD99 does not affect viability of human hematopoietic
and mesenchymal stem cells, constitutively expressing
high levels of CD99 [20, 38]. Here, we showed that
engagement of CD99 in mesenchymal stem cells did

In this paper, we provide the novel observation
that engagement of CD99 with the 0662mAb activated
a methuosis-like process that depends on the IGF-1R/

A

B

C

Figure 6: Rac1 inhibition reverts CD99-mediated effects. A. AO staining was performed in 6647 cells before (CTR) or after

exposure with 0662mAb (3h) alone or combined with the Rac1 inhibitor EHT 1864 (25 μM). For AO staining, cells were acquired using
the microscope Nikon ECLIPSE 90i with Plan Fluor 40x/0.75 DIC M/N2. Pictures provided are all merged images (scale bar 20μm). B.
Percentage of 6647 live cells before (-) and after (+) treatment with anti-CD99 0662mAb alone, or with Rac1 inhibitor EHT 1864 (25
μM for 48 h pretreatment) (trypan blue dye exclusion). C. Percentage of live 6647 cells before (-) and after (+) treatment with anti-CD99
0662mAb and/or with siRNA against Rac1. Cells were transfected by a scrambled (SCR) as control (trypan blue dye exclusion). Results
are expressed as mean ± SEM of three or more independent experiments (Student’s t test: *p< 0.05; **p<0.01).
www.impactjournals.com/oncotarget
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RAS/Rac1 signaling cascade and lead to cell death
in 13 patient-derived EWS cell lines, including those
resistant to conventional chemotherapy. We also provided
evidence that this mechanism is functional in 6647 EWS
xenografts derived from mice treated with anti-CD99
mAb, supporting the in vivo relevance of our study.
CD99 is expressed on the cell surface and it is detectable
in virtually all EWS cases [24]. CD99 is critical for
the pathogenesis of this tumor and it can be targeted in
combination with conventional treatments [20, 38]. Thus,
CD99 targeting has great clinical potential for EWS
therapy.
CD99 triggering by 0662mAb mimics apoptotic
stimuli [20, 21] but does not induce classical caspasedependent apoptosis and triggers caveolin-regulated but

clathrin-independent endocytosis, which accumulates
defective vacuoles in the cytoplasm, thereby compromising
viability. This process, known as methousis or death
by macropinocytosis, has been previously described
as an efficient mean of inducing cell death in different
types of cancers [8-12]. In contrast to physiological
macropinocytosis, methuosis is characterized by
dysregulated clearance of vacuoles associated with
insufficient recycling or fusion with other endosomal
compartments. The nascent vacuoles acquire late
endosomal/lysosomal markers such as LAMP-1 but do not
contain lysosomal enzymes and acidic pH, as is the case
of functional lysosomes [39]. Loss of viability may derive
from cytoplasmic hyper-vacuolization associated with loss
of metabolic capacity (decrease in ATP and mitochondrial

Figure 7: Rac1 colocalizes with CD99 and is sorted into vacuoles after 0662mAb treatment. In U2/CD99wt57 before (CTR)
and after 0662mAb treatment confocal microscopy shows colocalizations for A. CD99 (green) and Rac1 (red); B. Rac1 (green) and RAB5
(red); C. Rac1 (green) and LAMP-1 (red) (scale bar 20μm). Representative images are displayed. Colocalization index (MCC) represented
by histograms was calculated by Nis Elements AR4.20.01 software (Nikon) and expressed as mean values ± SEM (***p<0.001, Student’s
t test).
www.impactjournals.com/oncotarget
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potential) and plasma membrane integrity, without cell
shrinkage and nuclear fragmentation associated with
canonical apoptosis.
The signaling pathways that sustain methuosis are
in part cell system-dependent but few common features
have been so far defined. The process requires clathrinindependent endocytosis and mechanisms that converge
on the regulation of actin dynamics and RAS signaling.

Maltese and colleagues firstly provided the evidence
that induction of methuosis might only occur when the
level of active RAS reaches a threshold sufficient to
stimulate Rac1, thereby leading to inactivation of Arf6,
a small GTPase that promotes recycling from clathrinindependent endosomes to plasma membranes [13]. Thus,
Rac1-regulated vacuoles cannot recycle to the surface or
fuse to lysosomes; instead, they fuse to each other and

Figure 8: IGF-1R/RAS/Rac1 signaling is activated upon anti-CD99 treatment in vivo. A. Mean tumor volumes in control and

in CD99-antibody treated mice (Values are mean ± SEM, *p<0.05, Student’s t test). B. Representative immunohistochemical evaluation
of IGF-1R, RAS and Rac1 expression in untreated or anti-CD99 treated mice. Hematoxilin and Eosin staining was used to evaluate cell
morphology. Enlarged views of the boxed regions are shown below. Arrows indicate Rac1 positive vesicles (scale bar 50μm).
www.impactjournals.com/oncotarget
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late endosomes creating large vacuoles that accumulate
in the cytoplasm. The induction of methuosis caused by
overexpression of RAS (G12V) is a slow process and may
take several days. On the contrary, the anti-CD99 mAb as
well as small molecules that drive methuosis [8, 40] can
induce vacuolization within 1-4 hours, supporting their
possible application in the clinic. Intriguingly, the celldeath promoting role of RAS has been characterized in the

context of wild-type RAS up-regulation, whereas in cells
carrying RAS mutations macropinocytosis was described
as a mechanism supplying cancer cells with aminoacids to
sustain proliferation [41]. This might indicate a profound
difference between tumors with rare or high frequency of
RAS mutations, highlighting the importance of the cellular
context in defining therapeutic approaches. Significantly,
EWS belongs to the class of tumors with low rate of RAS

Figure 9: RAS and CD99 levels are crucial for 0662mAb-induced vacuolization. A. AO staining of human mesenchymal stem

cells (hMSCs) treated or not (CTR) with the anti-CD99 0662mAb. Representative merged images are shown (scale bar 20μm). B. Western
blotting evaluation of pan-RAS levels before (-) and after treatment with anti-CD99 0662mAb in 6647 cells or hMSC cells. GAPDH was
used as loading control. C. Left: AO staining of murine MSCs transfected with EWS/FLI1 and CD99 (C3H10T1/2 EF CD99) treated or
not (CTR) with the anti-CD99 0662mAb. Representative merged images are shown (scale bar 20μm). Right: western blotting evaluation
of pan-RAS levels before (-) and after treatment with 0662mAb in C3H10T1/2 EF CD99. GAPDH was used as loading control. D. Left:
AO staining of 6647/CD99low cells treated or not (CTR) with the anti-CD99 0662mAb. Representative merged images are shown (scale bar
20μm). Middle: western blotting evaluation of pan-RAS levels before (-) and after (+) treatment with 0662mAb for 1h in 6647/CD99low.
GAPDH was used as loading control. Right: percentage of live cells before (-) and after (+) treatment with anti-0662mAb in 6647/CD99low
(Annexin V/PI assay). Values represent mean ± SEM of three independent experiments (Student’s t test: p> 0.05).
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mutations [2, 42] suggesting that this particular tumor
context may favor RAS signaling and methuosis.
Here, we elucidated the molecular events that, upon
CD99 engagement, led to cell death and demonstrated
that CD99, when engaged by 0662mAb, rapidly
evokes caveolin-1-dependent endocytosis and fosters
up-regulation of IGF-1R and RAS/Rac1 induction.
Increased IGF-1R levels likely occurs through CD99induced degradation of MDM2 [20], which impairs IGF1R ubiquitination and degradation, as in fact MDM2,
in addition to control of p53 levels, also serves as an
ubiquitin ligase for the IGF-1R [43]. CD99 colocalizes
with caveolin-1 [26], the IGF-1R, RAS and Rac1 in
endosomes that are initially characterized by RAB5
expression and are later enriched in LAMP-1. However,
while CD99, RAS and Rac1 are then sorted into lateendosomes that may partially retain the ability to merge
with lysosomes, thereby inducing partial degradation of
the molecules, the IGF-1R is rapidly sorted back to the
cell surface through RAB11-dependent recycling. Thus,
IGF-1R recycling may constitute an additional mechanism
contributing to enhanced IGF-1R levels.
Stimulation of the IGF-1R was functionally
necessary for CD99-induced RAS up-regulation and
cell vacuolization. Considering that EWS cells display
autocrine activation of IGF-1R, its recycling to cell
membrane and consequent phosphorylation may work to
ensure the maintenance of sustained levels of RAS and
Rac1 signaling.
Inhibiting Rac1 interaction with its downstream
effectors by either specific inhibitors [35] or siRNA
approaches significantly inhibited CD99-induced
vacuolization and cell death, indicating that Rac1 induced
expression downstream of the IGF-1R/RAS complex is a
critical determinant of CD99-induced cell death. At least
two additional groups have identified small molecules
that specifically induce methuosis by mechanisms
dependent on Rac1 activity [8, 40]. Our work extends
these observations showing the up-regulation of IGF-1R/
RAS/Rac1 signaling after CD99 triggering in vivo and the
formation of Rac1-positive vesicles in responsive tumors.
The discovery that anti-CD99 0662mAb exerts
its anti-tumor action by enhancing IGF-1R/RAS/Rac1
activity may seem paradoxical. In fact, besides the
well-known role of IGF-1R in promoting EWS cell
malignancy [22, 44], Rac1 has been discovered as a key
mediator of EWS cell invasion and metastasis [45, 46].
However, we believe that the induction of methuosis may
explain this paradox. Rapid stimulation of physiological
macropinocytosis upon IGF-1 exposure is one of the early
events of IGF-1R signaling [47] and occurs to sustain
cell proliferation and survival. The interaction between
the IGF-1R and CD99, triggered by the 0662mAb,
may modify actin dynamics and shift physiological
macropinocytosis towards methuosis. Neither RAS nor
Rac1 are mutated in EWS [2, 42], where aberrant activity
www.impactjournals.com/oncotarget

is the result of altered expression and localization [11,
48]. Thus, CD99 may affect Rac1 downstream molecular
interactions and specificity of response by sequestering
RAS-Rac1 into vacuoles.
The results presented in this paper may have
important clinical implications. Our data suggest that
combining IGF-1R inhibitors with anti-CD99 mAb may
have an antagonistic effect. In contrast, CD99 triggering
exploits the constitutive activation of the IGF-1R, which is
sustained by EWS-FLI [49], and drives cells toward death.
Toxicity remains a major issue in the drug
development process and it is particular relevant for
pediatric diseases. Here we showed that treatment with
anti-CD99 0662mAb of normal human bone-marrow
derived MSC cells, expressing CD99 at levels similar
to EWS cells [20], did not induce hyperstimulation of
vacuoles or RAS up-regulation. Accordingly, MSC cells
are not susceptible to cell death, confirming previous
results in other cellular models [8, 11, 15, 41, 50]. When
MSC cells ectopically expressed EWS-FLI and CD99,
they regain the ability to respond to anti-CD99 antibody
entering a methuosis-like process. The effects are more
dramatic in malignant cells with higher expression of
CD99, as shown in CD99-resistant EWS cells. In addition,
reactivation of p53 following CD99 engagement [20] may
synergize with the death-promoting effects of RAS [51],
further increasing treatment efficacy. Both p53 reactivation
[20] and RAS induction could not be triggered in normal
MSC cells after treatment with anti-CD99.
Overall, our data prove that CD99-induced
macropinocytosis selectively destroys EWS cells, even
when they are chemoresistant. As of today, antibodies
against CD99 and few other small molecules are the
only agents that may specifically induce methuosis [8,
40]. CD99 triggering activates an “apoptotic mimicry”
mechanism that induces a methuosis-like process leading
to cell death. We clearly show that CD99-antibody
exploits a constitutively active IGF-1R to initiate RAS/
Rac1 signaling, defective vacuolization and death.
Interestingly, the process is enhanced in the presence of
high concentration of IGF-1, which leads to increased
percentage of EWS cell death. This is critical considering
that IGFs are the prevalent growth factors of bone. Their
release by tumor cell-induced bone destruction may
therefore activate an autocrine mechanism, which may
improve treatment efficacy against primary and metastatic
tumors.

MATERIALS AND METHODS
Cell lines and primary cell cultures
EWS cell lines were grown as previously described
[20, 26]. 6647 and TC-71 were kindly provided by T.J.
Triche (Children's Hospital, Los Angeles, CA, 1994);
RD-ES, SK-ES-1, SK-N-MC (1994) were provided by
79937
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American Type Culture Collection, ATCC (Rockville,
MD); H825 and H-1474-P2 were kindly provided by
Prof Llombart-Bosch (2001); C3H10T1/2 EF CD99 was
kindly provided by F. Lecanda, (2007) [52]. LAP-35
(1987); IOR/BRZ_2010 (1995); U2/CD99wt57 (2001)
[26]; TC-71 siIGF-1R (2006); TC/ET 12nM (2002) [53];
6647/CD99low (2009) [52] were previously established in
our laboratory; DOXO variants of TC-71 was obtained
by transfection with a vector containing MDR1 cDNA
and selected in doxorubicin (30ng/ml, SIGMA) [53].
LAP-35 variants stably overexpressing MDM2 were
previously characterized [20]. All cell lines were tested
for mycoplasma (MycoAlert mycoplasma detection kit,
Lonza) and authenticated by STR PCR analysis within
last year (GenePrint® 10 System or POWERPLEX EXS
17 fastsystem, Promega). Bone marrow-derived human
mesenchymal (hMSC) stem cells were obtained from
healthy donors or patients with benign bone lesions.
hMSC cells characterized for mesenchymal markers and
differentiative ability were used at early passages.

ml) were performed in adhesion or at the concentration of
5 × 106/ml cells as previously described [20, 21]. After the
indicated time-points, samples were tested for Annexin-V/
propidium iodide (Mebcyto apoptosis Kit, MBL), protein
extraction or specific assays. The following inhibitors
were used alone or in combination with 0662mAb:
necrostatin-1 (50μM), 3-methyladenine (3-MA) (5mM,
Sigma), Cytochalasin D (5μg/ml, Sigma) pre-treatment
at 37°C for 60 min, chlorpromazine (10μg/ml, Sigma)
pretreatment at 37°C for 30 min, anti-IGF-1R neutralizing
antibody AVE1642 [55] (100ng/ml, kindly provided by
ImmunoGen Inc), tyrosine kinase inhibitor NVP-AEW541
(1μM, kindly provided by Novartis) pre-treatment at 37°C
for 60 min. The Rac1 inhibitor, EHT 1864 (Tocris), was
added at 25μM in culture medium 24h after cell seeding
and renewed every day. After 48h of treatment, cells were
trypsinized, treated with 3μg/ml of 0662mAb for 4h and
harvested for vital count. 24h 1% FBS-starved cells were
treated with IGF-I (50ng/ml) alone or in combination with
0662mAb.

Stable and transient transfections and lentiviral
infections

Electron microscopy analysis
6647 and LAP-35 untreated or treated cells were
fixed with 2.5% glutaraldehyde in 0.1M cacodylate
buffer, pH 7.4, post-fixed with 1% OsO4, dehydrated to
absolute ethanol and embedded in Epon. Ultrathin sections
were stained with uranyl acetate and lead citrate before
observation with a Zeiss EM109 electron microscope.
Images were captured using a Nikon digital camera
Dmx1200F and ACT-1 software.

Transfections were performed using Calcium
Phosphate transfection Kit or Lipofectamine 2000 (Life
Technologies) according to the manufacturer’s protocol.
Transient transfection of MDM2 gene was performed
with pCMV-MDM2 [20]. Transient silencing of Rac1
was obtained by using anti-Rac1 oligos as previously
described [54]. For stable silencing of IGF-1R, TC-71
cells were transfected with pSilencer™ -2.1.U6 neo
(Ambion) containing the sequence for IGF-1R short
hairpin RNA and selected with G418 (500 μg/ml). 6647
and LAP-35 cells were infected with pBABEpuroHRASN17 or pBABEpuro empty vector supernatants,
and DN cells were selected with puromycin (500 ng/ml).
pLKO.1 shAtg7-E8 (TET-ON inducible) and pGIPZ sh
SCR (constitutive) were transfected on HEK293T cells
to generate lentiviral supernatant to infect 6647 cell line.
Cells were selected with puromycin (500 ng/ml). For
silencing induction cells were exposed to tetracycline
2.5μg/ml.

Flow cytometry and immunostaining

Sensitivity to chemotherapeutics was assessed
after 72h of treatment with TACS® MTT Cell
Proliferation Assay kit (TREVIGEN, Inc.) accordingly to
manufacturer’s instructions.

Standard protocols were followed as described
in Supplementary Materials and Methods). For
colocalization investigations by immunofluorescence
images were acquired and analyzed with a Nikon A1R
confocal microscope with a Plan Apo 60x/NA 1.4 DIC
N2. Pictures are representative of at least 10 independent
fields from three independent experiments. Fields were
selected for the presence of cells with the following
criteria: well defined limits, clear identification of
nucleus and absence of intersection with neighboring
cells. Colocalization analysis was performed both with
Pearson Colocalization Coefficient (PCC) and Mander’s
Colocalization Coefficient (MCC, shown in the paper)
and calculated by Nis Elements AR4.20.01 software
(Nikon). Colocalization index was represented by
histograms as mean ± SEM.

0662mAb and inhibitors treatment

Western blotting and immunoprecipitation

The anti-CD99 0662 monoclonal antibody (mAb)
was produced in the Unité INSERM 343, Hospital de
l’Archet, Nice, France. Treatments with 0662mAb (3μg/

Details
about
western
blotting
and
immunoprecipitation are provided in Supplementary
Materials and Methods.

Treatment with conventional drugs
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